Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 201–300 of 785
Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta‐analysis
Andersen, S. E., & Christensen, M. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13059 · Cited by 54
New treatments in type 2 diabetes: a focus on the incretin‐based therapies
Barnett, A. H. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 49
Cai, X., Han, X., Luo, Y., & Ji, L. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12196 · Cited by 51
C hina type 2 diabetes treatment status survey of treatment pattern of oral drugs users
Ji, L., Lu, J., Weng, J., Jia, W., Tian, H., Zhu, D., Xing, X., & Guo, L. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12165 · Cited by 49
Kim, S. A., Shim, W. H., Lee, E. H., Lee, Y. M., Beom, S. H., Kim, E. S., Yoo, J. S., Nam, J. S., Cho, M. H., Park, J. S., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.159 · Cited by 50
Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes
Henry, R. R., Smith, S. R., Schwartz, S. L., Mudaliar, S. R., Deacon, C. F., Holst, J. J., Duan, R. Y., Chen, R. S., & List, J. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01417.x · Cited by 49
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors
Åhrén, B. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0056-9 · Cited by 54
Montilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 49
The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
Pi-Sunyer, F. X. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1785 · Cited by 49
Kawalec, P., Mikrut, A., & Łopuch, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2494 · Cited by 51
Bergenstal, R. M., Forti, A., Chiasson, J.-L., Woloschak, M., Boldrin, M., & Balena, R. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0013-8 · Cited by 48
Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12395 · Cited by 48
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Ender, S. A., Machner, A., Pap, G., Hubbe, J., Graßhoff, H., & Hw, N. (2007) · Acta Orthopaedica · doi:10.1080/17453670710014301 · Cited by 48
Wainstein, J., Katz, L., Engel, S. S., Xu, L., Golm, G. T., Hussain, S., O’Neill, E. A., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01530.x · Cited by 48
Lim, S. K., An, J. H., Shin, H., Khang, A. R., Lee, Y., Ahn, H. Y., Yoon, J. W., Kang, S. M., Choi, S. H., Cho, Y. M., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04240.x · Cited by 46
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P., Bailey, C., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
Cefalu, W. T., Waldman, S. A., & Ryder, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100156 · Cited by 56
Update on the management of diabetes in long-term care facilities
Idrees, T., Castro-Revoredo, I. A., Migdal, A. L., Moreno, E. M., & Umpierrez, G. E. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002705 · Cited by 44
SUBBARAYAN, S. K., & Kipnes, M. S. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.580738 · Cited by 49
Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use
White, J. R. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.2.53 · Cited by 51
Lyu, X., Zhu, X., Zhao, B., Du, L., Chen, D., Wang, C., Liu, G., & Ran, X. (2017) · Scientific Reports · doi:10.1038/srep44865 · Cited by 50
Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
Bohannon, N. J. V. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.01.1953 · Cited by 49
Lotfy, M. A., Singh, J., Kalász, H., Tekes, K., & Adeghate, E. A. (2011) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501105010082 · Cited by 51
Oka, R., Yagi, K., Sakurai, M., Nakamura, K., Moriuchi, T., Miyamoto, S., Nohara, A., Kawashiri, M., Takeda, Y., & Yamagishi, M. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0157 · Cited by 44
Derosa, G., Ragonesi, P. D., Fogari, E., Cicero, A. F. G., Bianchi, L., Bonaventura, A., Romano, D., & Maffioli, P. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12001 · Cited by 50
Ousler, G. W., Anderson, R. T., & Osborn, K. E. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x260826 · Cited by 43
Rhee, E., Lee, W., Min, K. W., Shivane, V. K., Sosale, A., Jang, H. C., Chung, C. H., Nam‐Goong, I. S., Kim, J. A., Kim, S., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12060 · Cited by 47
DPP-4 Inhibitors in Clinical Practice
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2079 · Cited by 44
New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Green, J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3105 · Cited by 42
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
Åhrén, B. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s7327 · Cited by 55
Gliptins in managing diabetes - Reviewing computational strategy
Sneha, P., & Doss, C. G. P. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.009 · Cited by 48
Obesity and diabetes: the links and common approaches
Haslam, D. (2010) · Primary Care Diabetes · doi:10.1016/j.pcd.2010.04.002 · Cited by 42
Gibbs, J. P., Fredrickson, J. O., Barbee, T., Correa, I., Smith, B. P., Lin, S., & Gibbs, M. A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011420153 · Cited by 44
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, W., Xu, L., Zhang, H., & Li, Y. (2022) · BMJ · doi:10.1136/bmj-2021-068882 · Cited by 50
Intestinal mTOR regulates GLP-1 production in mouse L cells
Xu, G., Li, Z., Ding, L., Tang, H. W., Guo, S., Liang, H., Wang, H., & Zhang, W. (2015) · Diabetologia · doi:10.1007/s00125-015-3632-6 · Cited by 41
Tajima, N., Kadowaki, T., Odawara, M., Nishii, M., Taniguchi, T., & Ferreira, J. C. A. (2011) · Diabetology International · doi:10.1007/s13340-011-0022-2 · Cited by 45
DPP IV inhibitors: Successes, failures and future prospects
Kshirsagar, A. D., Aggarwal, A. S., Harle, U. N., & Deshpande, A. D. (2011) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.02.017 · Cited by 44
Dobs, A. S., Goldstein, B. J., Aschner, P. J., Horton, E. S., Umpierrez, G. E., DURAN, L., HILL, J. S., Chen, Y., Golm, G. T., Langdon, R. B., et al. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00223.x · Cited by 44
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Gilbert, M. P., & Pratley, R. E. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.011 · Cited by 43
Nagao, M., Sasaki, J., Sugihara, H., Tanimura‐Inagaki, K., Harada, T., Sakuma, I., Oikawa, S., STREAM Study Investigators, Asano, T., Aoyama, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-27301-9 · Cited by 54
Mathieu, C., Shankar, R. R., Lorber, D., Umpierrez, G. E., Wu, F., Xu, L., Golm, G. T., Latham, M., Kaufman, K. D., & Engel, S. S. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0105-3 · Cited by 42
Liu, S.-C., Chien, K., Wang, C., Chen, W.-C., & Cleunghen, C.-H. (2013) · Endocrine Practice · doi:10.4158/ep13148.or · Cited by 42
Rigby, S. P., Handelsman, Y., Lai, Y., Abby, S. L., Tao, B., & Jones, M. R. (2009) · Endocrine Practice · doi:10.4158/ep09146.or · Cited by 39
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats
Reimer, R. A., Grover, G. J., Koetzner, L., Gahler, R. J., Lyon, M. R., & Wood, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0484 · Cited by 45
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Riche, D. M., East, H. E., & Riche, K. D. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818eb721 · Cited by 44
Bonora, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01441.x · Cited by 43
Burgmaier, M., Heinrich, C., & Marx, N. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03746.x · Cited by 40
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 39
Lai, Z., Li, C., Liu, J., Kong, L., Wen, X., & Sun, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.044 · Cited by 39
Self-citationRamsey, S. D., Scoggins, J. F., Blough, D. K., McDermott, C. L., & Reyes, C. M. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.8.659 · Cited by 41
Vahed, T. A., Naimi‐Jamal, M. R., & Panahi, L. (2018) · New Journal of Chemistry · doi:10.1039/c8nj01946k · Cited by 40
Addition of incretin therapy to metformin in type 2 diabetes
Scheen, A. J., & Radermecker, R. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60399-6 · Cited by 43
Kelly, A. T., Sheikh, S., Stefanovski, D., Peleckis, A. J., Nyirjesy, S. C., Eiel, J. N., Sidhaye, A. R., Localio, R., Gallop, R., León, D. D. D., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab365 · Cited by 39
The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 45
Monteverde, A. P., Seck, T. L., Xu, L., Lee, M. A., Sisk, C. M., Williams‐Herman, D., Engel, S. S., Kaufman, K. D., & Goldstein, B. J. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02749.x · Cited by 44
Round, E., Engel, S. S., Golm, G. T., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0155-7 · Cited by 40
New technologies and therapies in the management of diabetes.
Triplitt, C. L. (2007) · PubMed · Cited by 44
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
Self-citationLi, C., Liu, X.-J., Bai, L., Yu, Q., Zhang, Q.-M., Yu, P., & Yu, D. M. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-69 · Cited by 37
Management and Treatment of Diabetes Mellitus
Imam, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_26 · Cited by 40
Chawla, S., Kaushik, N., Singh, N. P., Ghosh, R. K., & Saxena, A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.107656 · Cited by 37
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
Reid, T. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.1.3 · Cited by 35
Gross, J. L., Rogers, J. A., Polhamus, D. G., Gillespie, W. R., Friedrich, C., Gong, Y., Monz, B. U., Patel, S. D., Staab, A., & Retlich, S. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001844 · Cited by 38
Anti-diabetic medications: How to make a choice?
Babiker, A. M. I., & Dubayee, M. A. (2017) · Sudanese Journal of Paediatrics · doi:10.24911/sjp.2017.2.12 · Cited by 50
Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Wani, J. H., John‐Kalarickal, J., & Fonseca, V. A. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.06.008 · Cited by 37
Loh, H. H., Yee, A., Loh, H. S., Sukor, N., & Kamaruddin, N. A. (2015) · Primary care diabetes · doi:10.1016/j.pcd.2015.09.001 · Cited by 37
Davidson, J. A. (2013) · Endocrine Practice · doi:10.4158/ep12303.ra · Cited by 35
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 34
Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
Shigematsu, E. (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1889w · Cited by 38
Shim, J., Song, W., & Morice, A. H. (2020) · Physiological Research · doi:10.33549/physiolres.934406 · Cited by 33
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Aiysha Thompson, K. (2013) · Clinical & Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 33
Ji, L., Han, P., Wang, X., Liu, J., Zheng, S., Jou, Y., O’Neill, E. A., Golm, G. T., Engel, S. S., Kaufman, K. D., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12511 · Cited by 38
Self-citationHalimi, S. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73400-1 · Cited by 37
Gliptins: A new class of oral antidiabetic agents
Seshadri, K., & Kirubha, M. H. B. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.59541 · Cited by 35
Moses, R. G., Round, E., Shentu, Y., Golm, G. T., O'neill, E. A., Gantz, I., Engel, S. S., Kaufman, K. D., & Goldstein, B. J. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12351 · Cited by 32
Yano, W., Inoue, N., Ito, S., Ito, T., Yasumura, M., Yoshinaka, Y., Hagita, S., Goto, M., Nakagawa, T., Inoue, K., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12593 · Cited by 32
Shankar, R. R., Zeitler, P. S., Deeb, A., Jalaludin, M. Y., Garcia, R., Newfield, R. S., Самойлова, Ю. Г., Rosario, C. A., Shehadeh, N., Saha, C., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13279 · Cited by 32
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
Scheen, A. J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.513699 · Cited by 32
Mathieu, C., & Bollaerts, K. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01437.x · Cited by 33
Jalaludin, M. Y., Deeb, A., Zeitler, P., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., Zhang, Y., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13282 · Cited by 31
Shimoda, S., Iwashita, S., Ichimori, S., Matsuo, Y., Goto, R., Maeda, T., Matsuo, T., Sekigami, T., Kawashima, J., Kondo, T., et al. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0198 · Cited by 31
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38
Boland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 33
Barnett, A. H. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003738063 · Cited by 37
Fan, M., Li, Y., & Zhang, S. (2016) · Medicine · doi:10.1097/md.0000000000002386 · Cited by 38
The Role of Incretin Therapy at Different Stages of Diabetes
Cernea, S. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.323 · Cited by 35
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
Choe, E. Y., Cho, Y., Choi, Y., Yun, Y., Wang, H. J., Kwon, O., Lee, B., Ahn, C. W., Soo, B., Lee, H. C., et al. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.3.211 · Cited by 32
Zhu, J., Han, J., Liu, L., Liu, Y., Xu, W., Li, X., Yang, L., Gu, Y., Tang, W., Shi, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110568 · Cited by 34
Ma, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.009 · Cited by 35
Jost, M. M., Lamerz, J., Tammen, H., Menzel, C., Meester, I. D., Lambeir, A., Augustyns, K., Scharpé, S., Zucht, H. D., Rose, H., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.032 · Cited by 32
Drug evaluation: Vildagliptin-metformin single-tablet combination
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0010-0 · Cited by 31
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Srivastava, S., Saxena, G. N., Keshwani, P., & Gupta, R. (2012) · PubMed · Cited by 29
Yang, W., Cai, X., Zhang, S., Han, X., & Ji, L. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3391 · Cited by 32
Kazi, M., Alqahtani, A., Ahmad, A., Noman, O. M., Aldughaim, M. S., Alqahtani, A. S., & Alanazi, F. K. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1859001 · Cited by 31
Gallwitz, B., & Häring, H. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01095.x · Cited by 30
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
Bain, S., & Eligar, V. S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s32331 · Cited by 36
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.